Telemedicine and low-carbohydrate diet drive diabetes remission and medication reduction in long-term study

A recent study published in Diabetes Research and Clinical Practice has demonstrated the significant impact of a telemedicine intervention aimed at helping people living with type 2 diabetes (T2D) adhere to a very low-carbohydrate diet to induce nutritional ketosis. The findings show that this remote care approach led to notable health improvements over five years, including sustained weight loss, better cardiometabolic health, and reduced dependency on diabetes medications, with a remarkable portion of participants achieving long-term remission from the disease.

Study Background:

Historically, type 2 diabetes has been regarded as a chronic, progressive condition that requires lifelong management. However, emerging research has shown that certain therapies can effectively reverse the disease, lowering glycated haemoglobin (HbA1c) levels and reducing the need for glucose-lowering medications. This has opened the door to the possibility of medication-free diabetes remission, where HbA1c levels are maintained below 6.5% for at least three months without medication. Achieving remission is associated with significant long-term health benefits, as hyperglycaemia is linked to an increased risk of diabetes-related complications.

Among the various approaches to managing T2D, carbohydrate restriction has shown promise in improving cardiovascular health and glycaemic control. However, most studies have focused on shorter durations, often limited to two years or less. This study sought to explore the long-term effects of a telemedicine-driven, low-carbohydrate dietary intervention over five years.

Study Overview:

The study aimed to assess the long-term outcomes of a telemedicine intervention on individuals with T2D, examining factors such as blood sugar control, weight management, medication use, and overall cardiometabolic health. Participants were individuals living with T2D who had a body mass index (BMI) above 25. Initially, these participants were recruited for a two-year study comparing continuous care interventions (CCI) with usual care (UC). At the conclusion of the two years, participants in the CCI group were offered the opportunity to continue with the intervention for an additional three years.

Of the original 194 participants in the CCI group, 169 chose to continue for the full five years. The entire intervention was delivered remotely via a mobile application, without any in-person consultations. The app facilitated nutritional guidance and diabetes medication management, all handled through telemedicine.

Participants were encouraged to follow a highly restricted carbohydrate diet, consuming less than 30 grams of carbohydrates daily to achieve and maintain nutritional ketosis. The app allowed individuals to track their weight, blood glucose, and beta-hydroxybutyrate (BHB) levels, while also providing access to health coaches, physicians, and a peer support community.

Key Findings:

At the end of the five-year study, the average age of participants was 54.2 years, with nearly 68% of the cohort being female. Notably, 20% of the participants had achieved remission from diabetes, defined as HbA1c levels below 6.5% without the need for glucose-lowering medications or using only metformin. Among those who achieved remission at the two-year mark, an impressive 57.6% remained in remission at five years, demonstrating the durability of the intervention.

In terms of health improvements, participants saw a 0.3% reduction in HbA1c levels, a 7.6% decrease in body weight, and a 30.6% drop in fasting insulin levels over the course of the study. Cardiometabolic health markers also improved, with HDL cholesterol levels rising by 17.4% and high-sensitivity C-reactive protein (hs-CRP), an inflammation marker, dropping by 43.6%. These positive changes occurred despite a significant reduction in the use of diabetes medications.

A substantial proportion of participants experienced weight loss, with 61.3% achieving a 5% reduction in body weight and nearly 40% maintaining a 10% weight loss. Factors contributing to remission included lower fasting insulin levels, better adherence to the dietary protocol, weight loss, reduced reliance on potent diabetes medications, and a shorter duration of diabetes.

Over the course of the study, the proportion of participants using diabetes medications dropped from 85.2% to 71.3%. Use of medications other than metformin fell from 55.7% to 32.8%, and the average daily insulin dose significantly decreased from the baseline.

Statistical Analysis:

To evaluate the changes in health markers over time, the researchers employed a variety of statistical models. Linear mixed-effects models were used to account for within-subject variations and correlations over the five-year period. These models were adjusted for key covariates, including age, sex, and the duration of diabetes. The results showed statistically significant improvements in HbA1c, fasting insulin, and cardiovascular markers, confirming the robustness of the intervention’s effects.

Comparison with Other Studies:

When compared to other well-known lifestyle intervention trials, this study’s remission rates were notably higher. For instance, the Look AHEAD trial reported a remission rate of 7.3% over four years, and the DiRECT trial achieved a 13% remission rate after five years. In contrast, 20% of participants in this telemedicine intervention reached remission at five years, with 32.5% achieving HbA1c levels below 6.5% without the use of medication or only using metformin. The higher rates of remission in this study may be attributed to the sustained carbohydrate restriction and continuous support provided through the remote care model.

Conclusions:

The findings from this study suggest that a low-carbohydrate diet, combined with continuous remote care, can lead to significant long-term health benefits for people living with type 2 diabetes. After five years, 20% of participants had achieved diabetes remission, with 15 out of 24 participants maintaining remission for four consecutive years. Additionally, 32.5% of participants were able to achieve HbA1c levels below 6.5% without the need for glucose-lowering medications, or only using metformin.

Even those who did not reach full remission still experienced meaningful improvements, including stable blood glucose levels, reduced reliance on medications, and improvements in cardiovascular health. The study also highlighted the reduction in inflammation and other markers of cardiovascular risk, with a 40% decrease in the medication effect score further demonstrating the clinical value of this intervention.

The strengths of the study include its long duration and the broad applicability of the intervention, making it suitable for people with type 2 diabetes at various stages of the disease. However, it is worth noting the study’s limitations, including the absence of a comparison group over the full five-year period and the lack of racial diversity among the participants.

Overall, the study underscores the potential for telemedicine-driven, low-carbohydrate dietary interventions to provide lasting health benefits, including the possibility of diabetes remission and reduced medication dependence, for people living with type 2 diabetes.